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Abstract 
Rationale, Aims & Objectives: Pharmaceutical care involves patient-centred pharmacist 
activity to improve medicines management by patients. The implementation of this service 
in a comprehensive manner, however, requires considerable organisation and effort and 
indeed it is often not fully implemented in care settings.  
The main objective was to assess how pharmaceutical care provision within community 
pharmacy has evolved over time in Europe.  
Method: A cross-sectional questionnaire-based survey of community pharmacies, using a 
modified version of the Behavioural Pharmaceutical Care Scale (BPCS) was conducted 
in late 2012/early 2013 within 16 European countries and compared with an earlier 
assessment conducted in 2006.  
Results: The provision of comprehensive pharmaceutical care has slightly improved in all 
European countries that participated in both editions of this survey (n=8) with progress 
being made particularly in Denmark and Switzerland. Moreover, there was a wider 
country uptake, indicating spread of the concept. However, due to a number of limitations, 
the results should be interpreted with caution. Using combined data from participating 
countries, the provision of pharmaceutical care was positively correlated with the 
participation of the community pharmacists in patient-centred activities, routine use of 
pharmacy software with access to clinical data, participation in multi-disciplinary team 
meetings and having specialised education.  
Conclusion: The present study demonstrated a slight evolution in self-reported provision 
of pharmaceutical care by community pharmacists across Europe, as measured by the 
BPCS. The slow progress suggests a range of barriers which are preventing pharmacists 
moving beyond traditional roles. Support from professional bodies and more patient 
centred community pharmacy contracts, including remuneration for pharmaceutical care 
services, are likely to be required if quicker progress is to be made in the future.  
Keywords: pharmaceutical care; implementation; Europe; medication review; pharmacy 
services; medicines use 
 
 Introduction 
Within the context of pharmacy practice, during the last two decades, increased attention 
has been focused on the change in the community pharmacist’s role from product-focused 
to more patient-focused activities. With continued efforts to improve patient health 
outcomes, and in response to the challenge of a patient-focused approach, the concept of 
pharmaceutical care was developed in the US1 and was quickly adopted as “good 
pharmacy practice” internationally2. 
Delivery of pharmaceutical care has important demands on structure and process of the 
delivery of services in community pharmacies3. Different countries, according to the 
country-specific practice culture and systems of health delivery, have adopted 
pharmaceutical care services in different forms that match the local situation needs and 
which take into account various barriers and facilitating factors3. The concept of 
pharmaceutical care is complex and has continued to evolve over the years with many 
different definitions appearing in the literature.  In an attempt to harmonise definitions, 
the board of the Pharmaceutical Care Network Europe (PCNE) reached a consensus on a 
PCNE definition of Pharmaceutical Care, stating that it “is the pharmacist’s contribution 
to the care of individuals in order to optimise medicines use and improve health 
outcomes”4. 
A number of barriers have been identified internationally which have hindered the 
implementation of comprehensive pharmaceutical care programmes within community 
pharmacies, including: limited time, lack of reimbursement for the extra time required to 
deliver the service, high work load, inadequate competency and lack of commitment5-8. 
To facilitate the implementation of pharmaceutical care in the community pharmacy 
setting there is a need to build good relationships with general medical practitioners (GPs), 
to receive financial compensation for the service, to have the appropriate premises (e.g. 
private counselling area), to have appropriate and sufficiently trained staff, to have a high 
degree of co-ordinated teamwork and an ability to receive external guidance9. A conscious 
effort from individual pharmacists to deliver pharmaceutical care programmes and/or 
legislation that redefines the role the pharmacist is required to facilitate pharmaceutical 
care implementation10.  
Although the effectiveness of pharmaceutical care delivery has been largely defined in the 
context of research studies11, quantification of the service provided under everyday care 
conditions is important. A few studies describe the influence of the policy context in the 
implementation of services12, whilst others focus on structural influences, such as the 
existence of software capable of uploading identified drug-related problems into a national 
database13. The usual method to assess the provision of pharmaceutical care deployed in 
a large number of pharmacies is by the use of survey methodology, using a validated data 
collection instrument. Survey methodology compromises much of the pharmacy practice 
research literature corpus; it is surprising, however, that only a relatively few studies have 
assessed the degree of provision of pharmaceutical care in community pharmacies10, 14-21. 
The main aim of the present study was to assess the current degree of provision of 
pharmaceutical care by community pharmacists across Europe and to determine whether 
the degree of implementation had changed since 2006.  
 
Methods 
The provision of pharmaceutical care by community pharmacists across Europe was 
assessed through the co-operation of the Pharmaceutical Care Network Europe (PCNE, 
www.pcne.org). Having achieved the agreement of PCNE members from different 
European countries to participate, data were collected from 16 countries (Bosnia, 
Denmark, England, Germany, Italy, Lithuania, Malta, Moldova, the Netherlands, 
Northern Ireland, Norway, Portugal, Serbia, Spain, Sweden and Switzerland), with ethical 
approval being achieved as required by local regulation.  Belgium and the Ukraine 
engaged with the initiative but due to logistical reasons data collection/validation was 
delayed and has not been included in the analysis.  
Questionnaire/Instrument 
A validated instrument, with two separate sections, was used10,14. Section A collected data 
on pharmacists’ demographics and pharmacy services and layout. Section B evaluated the 
types of services provided to the last patients using the pharmacy (5 or 10) referring to a 
specific time period (2 or 6 weeks) using vignettes from a slightly modified version of the 
BPCS.  The vignettes describe different situations e.g. dealing with a first prescription or 
repeat dispensing. The BPCS comprises 34 items, which contribute to 3 domains, direct 
patient care activities (DPCA), referral and consultation activities (RCA) and instrumental 
activities (IA). This questionnaire has been previously used by researchers to assess the 
provision of pharmaceutical care by community pharmacists in Northern Ireland and then 
in a study across Europe10,15. The questionnaires were distributed late 2012/early 2013 i.e. 
the current survey is referred to throughout paper as 2013. 
 
Data collection 
The study was coordinated by Queen’s University Belfast and used PCNE to identify 
country coordinators. The country coordinators were responsible for determining the most 
effective manner to reach one pharmacist per pharmacy (i.e. pharmacist most involved in 
patient care activities) and they were informed on the sample size considered 
representative of their country, considering a confidence interval of 95%, a 3% error and 
a prevalence of the phenomenon (provision of Pharmaceutical care) ranging from 4.8% to 
25%, according to results from the previous study10. In countries that had not participated 
in the previous round, the lowest prevalence was considered, unless a national study could 
be used as reference (e.g. Spain). The method of distribution varied from country to 
country according to the available resources and research practice, i.e. online, face-to-face 
or via regular post. Most countries used an online survey method (Table 1). 
 
Data entry and analysis 
Data entry was the responsibility of each country coordinator, guided by a standard 
operating procedure to ensure quality22. Data obtained from the surveyed countries were 
uploaded into SPSS v19 for detailed statistical analysis and sent to the study coordinator. 
Standard statistical methodologies were used in the assessment of the provision of 
pharmaceutical care by community pharmacists. Descriptive statistics were used to 
summarise the data of all participating countries. Multiple pair-wise comparisons were 
carried out to compare the total and BPCS dimension scores between the participating 
countries. A Bonferroni adjustment for multiple comparisons was carried out. Dimension 
and total BPCS scores were also compared between the countries that participated in both 
editions of the survey (2006 v 2013), using the Wilcoxon test10. Pharmacist and pharmacy 
characteristics were explored for their association with the total BPCS scores, using 
combined data from all participating countries. Multiple linear regression modelling was 
used to identify factors contributing to the level of implementation as determined by the 
BPCS score. Statistical significance was set at p=0.05. As in previous research utilising 
the BPCS survey instrument, pharmacists who achieved a top quartile total BPCS score 
were categorised as providers of pharmaceutical care whereas pharmacists scoring in the 
bottom 25% were categorised as non-providers at the country level. Therefore the cut-off 
values used varies across countries.  
Results 
Response rate & practice demographics 
In eleven countries, the sample reached surpassed the estimated representative sample 
size. Countries below the estimates were Denmark, England, Malta, Northern Ireland and 
Switzerland. The response rate was considered too low for England to be valid and 
England was therefore removed from the comparative analysis. The remaining countries 
were included in the comparative analysis, however, significant caution should be used in 
interpretation of the data due to possible unrepresentativeness of the respondent sample 
(Table 1).  
The responding community pharmacists were more commonly (>50%) females in all of 
the surveyed countries except Italy, the Netherlands and Northern Ireland. Pharmacies had 
been instructed that the pharmacist with the most patient contact should take the lead in 
the survey, resulting in >60% of responding pharmacists with more than 5 years of 
experience in community pharmacy in all surveyed countries.  
 
Variations in pharmacy practice settings 
A wide distribution in the type and location of the pharmacies was noted in the surveyed 
countries. Pharmacy type ranged from 100% independent in Denmark, Germany and 
Spain to 89.6% large multiple in Serbia and 90.3% in Norway (Table 2). 
It was common for one full-time equivalent (FTE) pharmacist to work in each pharmacy 
in England, Malta, the Netherlands and Northern Ireland whereas the remainder of the 
surveyed countries had two or more pharmacists working in each pharmacy. In Sweden, 
46% of the respondents were “prescriptionists”, holding a BSc (Pharm) degree, while the 
remainder were pharmacists with a MSc (Pharm) degree. In all of the surveyed countries 
(except in Denmark, Germany, Norway, Serbia and Switzerland) there was, on average, 
two or fewer dispensing support staff working in the pharmacies. In half of the surveyed 
countries, the pharmacies on average dispensed >200 prescription items per day, while 
<200 items per day were dispensed in Bosnia, Germany, Italy, Lithuania, Malta, Moldova, 
Spain and Switzerland. A weak but significant correlation was noted between the number 
of prescription items dispensed per day and the number of FTE pharmacists (Spearman’s 
rho = 0.292; p<0.001) and FTE dispensing staff (Spearman’s rho = 0.328; p<0.001).   
In all surveyed countries, apart from the Netherlands, less than 50% of respondent 
pharmacists participated in multi-disciplinary team meetings. Private consultation areas 
were present to a large extent in pharmacies in all of the surveyed countries, with the 
exception of Lithuania, Moldova and Serbia. Most of the surveyed countries, except in 
Lithuania, Moldova and Serbia, routinely used customised pharmacy software to assist 
with the dispensing process. The extent of the use of software to check clinical data, drug 
interactions and contraindications by community pharmacists varied across the surveyed 
pharmacies. In all the surveyed countries, fewer than 50% of responding pharmacists 
indicated that patient-level clinical data were available via a shared database with the 
hospital or the GP. More than 25% of responding pharmacists, however, judged that these 
clinical data were easily accessed if required. Responding pharmacists participated in 
patient-centred services such as health screening, patient monitoring, medication review, 
and health promotion/education to a high extent in most surveyed countries, except for 
Moldova. A low participation was also found for Lithuania, Sweden and Denmark, with 
the exception made to medication review. Italy was actively engaged in two of these 
services (health promotion and education) but very little in the other services. It is also 
worth pointing out that in the Netherlands over 90% of responding pharmacists stated that 
they were engaged in medication review. Medication review was the most cited service 
by three of the surveyed countries: The Netherlands, Germany and Denmark (Table 2).  
BPCS scores  
The BPCS scores for each country are presented in Table 3. In the Netherlands survey, 
one of the items in the questionnaire from the referral and consultation dimension was 
inadvertently missed out; it was therefore not possible to calculate this dimension score 
and the total BPCS score for this country. 
The highest mean total BPCS scores were achieved by pharmacists from Switzerland 
(82.7/160) and Spain (80.2/160). Total BPCS scores achieved in Switzerland were 
significantly higher (p<0.05) than in the other surveyed countries. Moldova’s pharmacists 
scored the lowest mean total BPCS score (47.0/160). Graphical representations of the total 
and BPCS scores are presented in Figure 1. Lines have been inserted in the Figure at the 
BPCS scores of 50 and 70 which helps highlight the stage of evolution in each country 
towards comprehensive pharmaceutical care provision. 
Switzerland also achieved a high mean score for the direct patient care activities 
dimension (41.5/85), with the Netherlands, Portugal and Germany also scoring highly in 
this dimension (34.8, 34.7 and 33.0/85). The lowest mean direct patient care activities 
dimension score was achieved in Moldova (13.4/85).  
The highest mean referral and consultation activity dimension score was noted in 
Denmark and Spain (28.7 and 28.6/40), while the lowest score in this dimension was 
achieved in Moldova (16.3/40). Referral and consultation activity scores achieved in 
Spain were significantly higher (p<0.05) than in other countries.  
The highest mean instrumental activity dimension score was noted in the Netherlands 
(26.6/35), while again the lowest score was achieved in Moldova (17.3/35). Instrumental 
activity scores achieved in the Netherlands were significantly (p<0.05) higher than in the 
other surveyed countries.  
Providers and non-providers of pharmaceutical care 
In accordance with the original questionnaire designers14, at country level, pharmacies 
achieving BPCS scores within the top 25% were considered providers of pharmaceutical 
care while those in the bottom 25% were considered non-providers (Table 4). 
Evolution of pharmaceutical care provision over time 
Total BPCS scores remained static or evolved positively, although in some cases 
marginally, over time for the countries that engaged (between the 2006 and 2013 surveys) 
i.e. Denmark, Germany, Malta, Northern Ireland, Portugal, Sweden and Switzerland. 
Denmark and Switzerland were the only two countries which achieved a step change in 
the total score achieved. 
Direct patient care activity scores obtained in the 2013 study were significantly higher 
(p<0.05) than those achieved in the 2006 survey. Referral and consultation dimension 
scores in the present study were, however, significantly lower (p<0.05) than those 
obtained in the 2006 survey. No significant differences between 2006 and 2013 data were 
noted for the instrumental activity scores (Table 5). 
Factors associated with pharmaceutical care provision 
Thirteen variables were investigated as factors associated with the mean total BPCS scores 
achieved using combined data from all of the countries surveyed in 2013. Variables that 
showed a trend of association with the total BPCS score were identified through an initial 
multiple linear regression model. Significant variables obtained from this model were 
entered into a final linear regression model. A ten-variable model was constructed 
explaining 40% of the variability of the outcome (total BPCS score). The most influential 
variable in the model which was positively associated with high total BPCS scores was 
participation in medication review (Table 6).  
Discussion  
Patient-centred care provision has been proposed as a means to address the challenges of 
medication-related problems, including ensuring high medication appropriateness and 
medication adherence to prescribed treatments and associated life-style factors23. 
Pharmaceutical care has been viewed as one of the most important roles of the pharmacist 
and, when appropriately implemented, has been shown to have a positive impact on 
patient health outcomes11. The present study assessed the provision of pharmaceutical care 
by community pharmacists across Europe. 
The pharmaceutical care concept has been in place for a considerable time (since early 
1990s), and progressive evolution seems to be happening in Europe. Countries that have 
implemented the concept over a long period, are improving. On the other hand, it is clear 
that countries which until recently  had more traditional roles are becoming more aware 
of pharmaceutical care, by their expressed desire to join the research programme and 
perhaps as a result of both national and international bodies investing in their full 
integration in Europe. It is worth noting, that although the scores for the Eastern Europe 
countries were quite low, there was considerable variability among them, perhaps as a 
result of different policy measures being adopted.  
Response rate 
The response rate to a questionnaire is an important issue, as a low rate can increase the 
risk of bias in the answers received24. The response rate varied from 1.6% in Spain (but 
since 346 pharmacies participated, the sample exceeded the minimum estimated sample 
size required) to 99.0% in Bosnia. The differences in the response rates between countries 
can be attributed to the different survey distribution methodology used (online, postal or 
face-to-face interview) as well as the variable involvement of national organisations able 
to motivate response. However, more important than the sample size is its 
representativeness, assessed by how number of responses compares with national data. 
On this aspect, it should be noted that the presence of selection bias cannot be disregarded 
for Sweden, judging by the proportion of pharmacists versus prescriptionists among the 
respondents, compared to their proportions within the community pharmacy work force. 
In addition a much lower response rate was achieved in Sweden in the second assessment 
(28.4%; 2013) than in the first survey (70.9%; 2006).    
Demographics & practice characteristics 
Community pharmacists from most European countries frequently provided additional 
services and used computer software routinely when dealing with individual patients. Of 
note there was a marked increase in the percentage of pharmacies in a number of European 
countries (N. Ireland, Portugal, Sweden and Switzerland) having a private consultation 
area when compared with findings from the 2006 study10. This provides a basis/facilitator 
for high quality clinical care for patients which can be seen as a positive advancement 
from the 2006 study.  
Provision of pharmaceutical care 
The present study showed that the mean score for the community pharmacists across the 
surveyed European countries was 69.3/160 (43.3%). The total BPCS scores achieved 
across different European countries ranged from 47.0 (Moldova) to 82.7 (Switzerland). 
These findings suggest that the provision of pharmaceutical care by community 
pharmacists still remains limited across Europe. Individual studies across other countries, 
including the US, Denmark, Spain, Northwest China and Jordan, have also highlighted 
the issue of low provision of pharmaceutical care by community pharmacists14, 16-21. 
Lack of time and resources has repeatedly been found as the main reasons for the lack of 
provision of comprehensive pharmaceutical care in the community pharmacy setting 
internationally5,6,9,25. Other studies have suggested that lack of commitment among 
pharmacy practitioners to pharmaceutical care as a major barrier for implementation8. 
Although not specifically examined in the present study, it is likely that these remain 
major barriers. In addition, due to the variability between results for individual pharmacies 
within each country, the present findings indicate a lack of standardised policies and/or 
procedures for the delivery of pharmaceutical care.  
In order to promote a more patient centred approach to pharmacy practice, a number of 
motivators for the provision of pharmaceutical care have been put into place in a number 
of European countries in the period covered by the overall study (2006-2013)3. In 
Northern Ireland, for example, a number of patient-centred services have been 
commissioned by the nationalised health service which include a medicines management 
initiative, repeat prescription scheme, minor ailments scheme, smoking cessation service 
and advice to nursing and residential homes (HSC Business Service Organisation web 
site; http://www.hscbusiness. hscni.net/services/1944.htm). In Portugal, pharmacists have 
been remunerated for the provision of additional services to patients with diabetes26. A 
system for the documentation of medication-related problems has been available in all 
community pharmacies in Sweden3,13. Reimbursement for certain elements of 
pharmaceutical care has been agreed in the Netherlands, Switzerland, Germany and in 
Great Britain27. To promote best practice, the Royal Pharmaceutical Society of Great 
Britain has launched an early adopter programme which specifically addressed ‘keeping 
patients safe when they transfer between care providers’ with a focus on medicines 
management across interfaces28. Such early adopter programmes, in which pioneer 
pharmacists initially provide and refine new care delivery approaches, promotes the 
application of new care models into routine practice29.  
However, when compared with the results reported in the 2006 survey10, the mean total 
BPCS scores improved for several countries. Although differing response rates may have 
been at least in part responsible for the improvements in some countries, the results seem 
highly plausible. For instance, in Portugal, the fact that pharmaceutical care has been 
legally recognised in 2007 cannot be disregarded30. Moreover, in Switzerland, the 
introduction of remunerated medicines use review in 2010 is very likely to have driven 
the observed increase31. In Germany, the development of a nationwide service in 
medication review was launched in 2011; since then, two main studies have been rolled 
out, the ARMIN study, which runs in two states and is being remunerated 
(www.arzneimittelinitiative.de) and the ATHINA study, which currently is still not 
remunerated. The sharp increase observed in Denmark also seems consistent with data 
reported elsewhere, influenced by various ongoing projects32. 
In general, Direct Patient Care Activity scores were higher in the present study, whilst the 
Referral and Consultation Activities decreased compared to the 2006 study. The latter 
finding, if viewed from an optimistic perspective, may be seen as a positive result.  The  
decrease in referral might reflect a more active and independent approach by pharmacists 
in solving drug related problems and care issues, perhaps supported by system changes, 
increased availability of private consultation rooms and the introduction of a number of 
recognised remunerated services. 
The differences in domain, dimension and total scores between countries represent 
heterogeneity in the primary care systems across Europe as well as the lack of harmonised 
policies and procedures for the delivery of pharmaceutical care30,33. A trend of low 
provision of patient assessment, documentation activities, implementation of therapeutic 
objectives and monitoring plans, and direct patient activities overall was noted in the 
surveyed European countries. This low provision is associated with tasks that are time 
consuming. The low level of documentation of activities is considered particularly 
problematic, since in the absence of documentation, follow-up is difficult, i.e. without 
benchmark data and without therapeutic objectives or monitoring plans being recorded. 
Moreover, lack of documentation will ultimately delay or even be a barrier for successful 
negotiation of remuneration, as evidence of the impact of the service cannot be gathered. 
The present study confirmed that a number of pharmaceutical care activities have been 
implemented into daily practice including screening activities, patient counselling, 
medication review, verification of patient understanding and the use of a private area for 
patient counselling. However, many activities were lacking in countries with less 
developed pharmacy systems (e.g. Moldova and Lithuania). These findings are in line 
with the results reported across Europe in 2006 and in the earlier Northern Irish results of 
199610,15.  
 
 
Providers versus non-providers of pharmaceutical care 
The present study showed that the percentage of respondents who were judged to be 
providers of pharmaceutical care, using the methodology suggested by Odedina and 
colleagues14 (top 25% of BPCS scores), was less than those deemed non-providers 
(bottom 25% of BPCS scores) in the European countries. 
Pharmaceutical care is of course not a service delivered by a pharmacist in isolation from 
other healthcare professions. Participation in multidisciplinary meetings can help build 
professional relationships and help in the initiation of discussions about different patient 
cases. This type of activity has also been documented as a facilitator to pharmaceutical 
care, with a particular emphasis on relationships with physicians9. In addition, 
pharmaceutical care delivery is expected to be enhanced when related services such as 
health screening, patient monitoring, medication review and health promotion/education 
are delivered within the pharmacy. This association was noted in both the present study 
and the 2006 study. The importance of appropriate software cannot be overemphasised as 
this can aid in the decision making and in the documentation of different services. Access 
to medical notes/clinical information is of paramount importance in the delivery of 
comprehensive pharmaceutical care, and limited access to patient medical details has been 
identified by others as a barrier to the provision of pharmaceutical care25. Findings from 
the present study (having a postgraduate qualification in pharmacy and a high number 
prescription items dispensed in an average day) were also highlighted as facilitators to 
pharmaceutical care provision in a US study16. This latter study found that the predictors 
for pharmaceutical care service provision included pharmacists holding a postgraduate 
qualification, the pharmacy being located in a clinic, the pharmacy being independent and 
a high number of prescriptions dispensed per day16.  
It should be acknowledged that the slow evolution in the provision of pharmaceutical care, 
is unlikely to change without significant intervention at the system level (e.g. new 
community pharmacy contracts), with adequate remuneration for patient-centred services. 
Gathering evidence at the national level, coupled with lobbying activities should be 
influential in changing policy, ultimately leading to improved practice. 
 
Limitations 
The different survey methodology approaches, coupled with low response rates achieved 
in a number of countries, represent the major limitation of this study indicating that results 
may not be generalizable, due to a likely selection bias. Furthermore, the provision of 
pharmaceutical care was self-reported and self-rated, which may lead to over reporting of 
good practice initiatives.  
Conclusions  
The present study demonstrated the evolution in self-reported provision of pharmaceutical 
care by community pharmacists across Europe, as measured by the total BPCS scores. 
Community pharmacists’ provision of pharmaceutical care across Europe was positively 
associated with participation in additional services (health screening, patient monitoring, 
medication review and health promotion/education); participation in multidisciplinary 
team meetings; routine use of pharmacy software when checking clinical data and drug-
drug interactions; access to clinical data (clinical data available through shared 
database/easily accessed); postgraduate qualifications in pharmacy; working in a 
pharmacy that has a private patient consultation area; and a high number of prescription 
items dispensed on an average day. Scores obtained by new European countries suggest 
they are at a later stage of implementation. The BPCS tool has proven to be useful in 
detecting changes over time despite the limiting factors.  New approaches to enhance 
recruitment into future surveys, for example, providing a reward for completion, could be 
used to help encourage a higher uptake, thus avoiding selection bias.  
Author contribution: This project was initiated by James McElnay and Tommy 
Westerlund and the project delivery team was chaired by James McElnay. The data 
analysis and initial manuscript were performed by Ghaith Al- Tanni, Ahmed F. Hawwa, 
Claire Scullin and James McElnay; the manuscript was finalized by Filipa Alves da Costa, 
Kurt E Hersberger and Tommy Westerlund. The other authors were members of the PCNE 
BPCS Project Team who led the survey in their respective countries. 
 
 
 
References  
1. Hepler, C.D. and Strand, L.M. Opportunities and responsibilities in pharmaceutical 
care. American Journal of Hospital Pharmacy.1990;47(3):533-543.  
2. International Pharmaceutical Federation, 2000-last update, FIP statement of policy on 
good pharmacy education practice [Homepage of International Pharmaceutical 
Federation], [Online]. http://www.fip.org/www/uploads/database_file.php?id=188 
(accessed 26 January 2013).  
3. Farris, K.B., Fernandez-Llimós, F. and Benrimoj, S.I. Pharmaceutical care in 
community pharmacies: Practice and research from around the world. Annals of 
Pharmacotherapy. 2005; 39(9): 1539-1541.  
4. Allemann, S.S., van Mil, J.W.F., Botermann, L., Berger, K., Griese, N., Hersberger, 
K.E. Pharmaceutical Care: The PCNE definition 2013. International Journal of Clinical 
Pharmacy. 2014; 36 (3): 544-55 
5. Van Mil, J.W.F., De Boer, W.O. and Tromp, T.F.J. European barriers to the 
implementation of pharmaceutical care. International Journal of Pharmacy Practice. 
2001;9(3): 163-168.  
6. Blake, K.B. and Madhavan, S.S.. Perceived barriers to provision of Medication Therapy 
Management Services (MTMS) and the likelihood of a pharmacist to work in a pharmacy 
that provides MTMS. Annals of Pharmacotherapy. 2010;44(3): 424-431.  
7. Roberts, A. S., Benrimoj, S., Chen, T. F., Williams, K. a, & Aslani, P.  Implementing 
cognitive services in community pharmacy: a review of models and frameworks for 
change. International Journal of Pharmacy Practice. 2006; 14(2): 105–113.  
8. Westerlund LOT, Handl WHA, Marklund BRG, Allebeck P. Pharmacy practitioners’ 
views on computerized documentation of drug-related problems. Annals of 
Pharmacotherapy. 2003; 37:354–60.  
9. Roberts, A.S., Benrimoj, S.I., Chen, T.F., Williams, K.A. and Aslani, P. Practice change 
in community pharmacy: Quantification of facilitators. Annals of Pharmacotherapy. 
2008;42(6): 861-868.  
10. Hughes, C.M., Hawwa, A.F., Scullin, C., Anderson, C., Bernsten, C.B., Bjornsdóttir, 
I., Cordina, M.A., da Costa, F.A., De Wulf, I., Eichenberger, P., Foulon, V., Henman, 
M.C., Hersberger, K.E., Schaefer, M.A., Sondergaard, B., Tully, M.P., Westerlund, T. and 
McElnay, J.C. Provision of pharmaceutical care by community pharmacists: A 
comparison across Europe. Pharmacy World and Science. 2010; 32(4): 472-487.  
11. Roughead, E.E., Semple, S.J. and Vitry, A.I.. Pharmaceutical care services: A 
systematic review of published studies, 1990 to 2003, examining effectiveness in 
improving patient outcomes. International Journal of Pharmacy Practice. 2005; 13(1): 53-
70.  
12. Kaes, S, Traulsen, JM, Søndergaard, B, Haugbølle, L.S. The relevance of political 
prestudies for implementation studies of cognitive services in community pharmacies. 
Research in Social and Administrative Pharmacy. 2009; 5: 189–194. 
13. Westerlund T, Gelin U, Pettersson E, Skärlund F, Wågström K, Ringbom C. A 
retrospective analysis of drug-related problems documented in a national database. 
International Journal of Clinical Pharmacy. 2013;35(2): 202-9. 
14. Odedina, F.T. and Segal, R. Behavioral pharmaceutical care scale for measuring 
pharmacists' activities. American Journal of Health-System Pharmacy. 1996; 53(8): 855-
865.  
15. Bell, H.M., McElnay, J.C., Hughes, C.M. and Woods, A. Provision of pharmaceutical 
care by community pharmacists in Northern Ireland. American Journal of Health-System 
Pharmacy. 1998;55(19):2009-2013.  
16. McDermott, J.H. and Christensen, D.B. Provision of pharmaceutical care services in 
North Carolina: a 1999 survey. Journal of the American Pharmaceutical Association 
(Washington, D.C.: 1996). 2002; 42(1):26-35.  
17. Rossing, C., Hansen, E.H. and Krass, I. The provision of pharmaceutical care in 
Denmark: A cross-sectional survey. Journal of clinical pharmacy and therapeutics. 
2003;28(4):311-318.  
18. Rossing, C., Hansen, E.H., Traulsen, J.M. and Krass, I. Actual and perceived provision 
of pharmaceutical care in Danish community pharmacies: The pharmacists' opinions. 
Pharmacy World and Science. 2005;27(3): 175-181.  
19. Zardaín, E., Del Valle, M.O., Loza, M.I., García, E., Lana, A., Markham, W.A. and 
López, M.L. Psychosocial and behavioural determinants of the implementation of 
Pharmaceutical Care in Spain. Pharmacy World and Science. 2009;31(2):174-182.  
20. Fang, Y., Yang, S., Feng, B., Ni, Y. and Zhang, K. Pharmacists' perception of 
pharmaceutical care in community pharmacy: A questionnaire survey in Northwest China. 
Health and Social Care in the Community. 2011;19(2): 189-197.  
21. Aburuz, S., Al-Ghazawi, M. and Snyder, A.. Pharmaceutical care in a community-
based practice setting in Jordan: Where are we now with our attitudes and perceived 
barriers? International Journal of Pharmacy Practice. 2012;20(2):71-79.  
22. Besterfield, D. H. 1990, Quality Control, Third edn, Prentice Hall, New Jersey. 
23. Kennie-Kaulbach, N., Farrell, B., Ward, N., Johnston, S., Gubbels, A., Eguale, T., 
Dolovich, L., Jorgenson, D., Waite, N. and Winslade, N., 2012. Pharmacist provision of 
primary health care: A modified Delphi validation of pharmacists' competencies. BMC 
Family Practice. 2012;13:27. DOI: 10.1186/1471-2296-13-27  
24. Edwwards, P.J., Roberts, I.G., Clarke, M.J., Diguiseppi, C., Wentz, R., Kwan, I., 
Cooper, R., Felix, L. and Pratap, S.. Methods to increase response rates to postal and 
electronic questionnaires. Cochrane Database of Systematic Reviews, 2009; 3 
25. Dunlop, J.A. and Shaw, J.P. Community pharmacists' perspectives on pharmaceutical 
care implementation in New Zealand. Pharmacy World and Science. 2002;24(6):224-230.  
26. Bulajeva, A., Labberton, L., Leikola, S., Pohjanoska-Mantyla, M., Geurts, M.M., de 
Gier, J.J., Airaksinen, M. Medication review practices in European countries. Research in 
Social and Administrative Pharmacy. 2014;10(5):731-40 
27. van Mil JW, Schulz M, Tromp TF. Pharmaceutical care, European developments in 
concepts, implementation, teaching, and research: a review. Pharm World Sci. 2004; 
26(6):303-11. 
28. Royal Pharmaceutical Society, 2012. http://www.rpharms.com/getting-the-medicines-
right/early-adopters.asp (accessed 26 November 2016)  
29. Posey, L.M. Proving that pharmaceutical care makes a difference in community 
pharmacy. Journal of the American Pharmacy Association (Wash). 2003; 43(2):136-9 
30. Martins, S., van Mil, JWF, Costa F.A. The organizational framework of community 
pharmacies in Europe. International Journal of Clinical Pharmacy. 2015; 37(5):896-905.  
31. Messerli, M, Blozik, E, Vriends, N, Hersberger, KE. Impact of a community 
pharmacist-led medication review on medicines use in patients on polypharmacy--a 
prospective randomised controlled trial. BMC Health Serv Res 2016; 16(1):145. doi: 
10.1186/s12913-016-1384-8 
32. Søndergaard, B. Implementation of Pharmacy Services in Denmark. FIP, 2015. 
33. Van Mil, J.W. and Schulz, M. A review of pharmaceutical care in community 
pharmacy in Europe. Harvard Health Policy Review. 2006;7(1):155-168.  
 
Table 1 Response rate to 2013 BPCS survey administration across European countries  
Country Survey 
methodology 
 
Number of 
existing 
pharmacies 
Prevalence 
considered1 
(%) 
Sample 
estimated 
(n) 
Respondents 
(n) 
 
Response  
rate (%) 
Bosnia Online 100 4.8 66 99 99.0 
Denmark Online 300 4.8 118 90 30.0 
England Online 9,2252 9.9 337 78 0.9 
Germany Online 5,968 21.5 643 722 12.1 
Italy Online 17,000 4.8 193 807 4.7 
Lithuania Face to face 
interview 
1,370 4.8 171 227 16.6 
Malta Postal 213 11.6 143 83 39.0 
Moldova Online and 
postal 
400 4.8 131 315 78.8 
Netherlands Online 1,966 4.8 178 209 10.6 
Northern 
Ireland 
Postal 549 25.0 326 150 27.3 
Norway Postal 679 4.8 152 257 37.8 
Portugal Online 2,937 17.4 508 686 23.4 
Serbia Postal 528 4.8 143 374 70.8 
Spain Online 21,458 9.0 344 346 1.6 
Sweden Online 1,318 6.2 209 375 28.4 
Switzerland Online 1 ,757 22.4 522 390 22.2 
1The prevalence value was obtained from results of the 2006 study.  For those not 
participating in the 2006 study, the lowest level of implementation was used. 
2Link to the online survey included in general pharmacy correspondence.
 
Table 2 Demographic and practice characteristics (expressed in percentages) of the responding pharmacists (across Europe, 2013) 
 
Characteristics Bosnia Denmark Germa  
ny 
Italy Lithuania Malta Moldova Netherl 
 
ands 
N. 
 
Ireland 
Norwa 
 
y 
Portu 
 
gal 
Serbia Spain Sweden Switzerla 
 
nd 
Gender 
Male 46.5 15.7 49.2 62.9 5.3 27.7 7.9 56.0 51.3 16.7 27.2 9.1 35.5 15.2 42.3
Female 53.5 84.3 50.8 37.1 94.7 72.3 92.1 44.0 48.7 83.3 72.8 90.9 64.5 84.8 57.7
Missing 0.0 1.1 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 0.0 1.8
Years of experience in community pharmacy 
≤5 years 4.0 37.1 8.7 2.0 12.9 31.3 19.4 14.8 16.2 24.1 33.4 24.1 15.1 35.4 8.8
6–10 11.1 23.6 12.2 5.6 11.0 13.3 23.8 19.1 27.0 26.8 26.4 23.8 20.9 18.5 10.4
11–20 37.4 13.5 33.1 21.9 16.8 37.3 25.1 31.1 27.0 24.1 28.8 24.9 32.8 16.9 29.6
>20 47.5 25.8 46.1 70.5 59.4 18.1 31.7 34.9 29.7 24.9 11.3 27.3 31.3 29.2 51.2
Missing 0.0 1.1 1.1 0.0 31.7 0.0 0.0 0.0 1.3 0.0 2.3 0.0 0.3 0.5 1.3
Type of pharmacy 
Independent 43.4 100.0 53.7 76.7 17.6 74.7 7.1 53.1 52.7 9.7 78.3 0.3 100.0 15.7 35.1
 
  
    
Small multiple 
 
(5–10 
pharmacies) 
56.6 0.0 8.0 23.3 3.1 24.1 9.6 11.5 8.0 0.0 21.7 10.2 0.0 2.7 5.6
Large multiple 
 
(>10 pharmacies) 
0.0 0.0 38.2 0.0 79.3 1.2 83.3 35.4 39.3 90.3 0.0 89.6 0.0 81.6 59.2
Missing 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 2.0 0.0 0.0 0.0 0.0
Location of the pharmacy 
Rural 0.0 11.6 37.5 44.2 1.3 20.5 6.4 20.1 28.9 0.0 23.0 13.6 41.4 12.8 32.3
Suburban 33.3 14.0 23.0 23.9 40.5 20.5 9.9 22.0 24.2 0.0 25.7 11.8 40.8 9.6 22.6
City or Town 
 
Centre 
60.6 73.3 16.9 31.8 54.6 59.0 78.0 21.5 43.0 0.0 51.3 56.4 12.0 54.4 34.9
Health Centre 6.1 1.2 22.6 0.0 3.5 0.0 5.8 36.4 4.0 0.0 0.0 18.2 5.8 23.2 10.3
Missing 0.0 4.4 0.0 0.0 0.0 0.0 0.6 0.0 0.7 100.0 1.9 0.0 10.7 0.0 0.0
No. of pharmacists who work in the pharmacy (FTE) 
1 9.1 5.7 29.9 17.1 36.2 63.9 1.3 63.2 62.4 8.0 10.2 36.2 30.5 6.0 24.4
 
  
    
2 19.2 27.3 48.7 29.5 36.7 28.9 10.3 29.2 28.2 30.7 34.4 25.5 41.9 15.3 56.3
3 16.2 42.0 15.0 20.9 14.3 6.0 62.8 5.7 5.4 36.5 28.8 13.1 19.5 26.7 15.2
≥4 55.6 25.0 6.3 32.5 12.9 1.2 25.6 1.9 4.0 24.8 26.6 25.2 8.1 52.0 4.1
Missing 0.0 2.2 1.4 0.0 7.5 0.0 0.0 0.0 0.7 46.7 4.2 0.3 0.6 2.1 0.3
No. of skilled staff in the pharmacy (FTE) 
0 0.0 0.0 2.3 46.8 24.3 32.5 93.9 85.6 9.5 9.2 7.7 8.0 21.0 39.4 0.8
1 20.2 2.5 23.7 32.1 39.2 34.9 4.8 12.9 31.3 19.1 22.2 20.9 38.6 27.2 7.2
2 44.4 0.0 33.7 16.9 24.3 24.1 1.3 1.0 27.9 26.2 31.1 24.4 27.4 15.9 19.8
3 15.2 2.5 22.4 2.9 4.5 6.0 0.0 0.5 16.3 12.8 21.1 17.7 10.9 9.2 24.2
≥4 20.2 95.1 18.0 1.4 7.7 2.4 0.0 0.0 15.0 32.6 17.8 29.0 2.1 8.4 47.9
Missing 0.0 10.0 1.7 0.0 2.2 0.0 0.3 0.0 2.0 45.1 3.5 0.3 4.9 1.1 0.5
Pre-registration student engaged in the pharmacy 
Yes 44.4 50.0 16.1 29.6 22.0 41.5 5.1 12.9 40.1 24.1 24.7 34.6 17.3 15.7 18.3
Missing 0.0 4.4 1.1 0.0 0.0 1.2 0.0 0.0 2.0 0.0 2.2 1.9 1.2 0.0 0.5
No. of prescription items dispensed per day 
0-99 75.8 3.3 19.2 38.8 78.8 96.4 15.1 1.0 7.5 15.7 9.6 31.6 31.3 14.9 35.3
 
  
    
100–199 15.2 1.7 37.6 45.8 15.9 3.6 71.5 5.7 25.2 32.6 35.3 16.1 38.3 31.0 28.4
200–299 6.1 0.0 26.3 13.1 1.0 0.0 13.5 16.7 18.4 29.8 25.9 11.0 19.9 22.8 14.5
≥300 3.0 95.0 16.9 2.2 4.3 0.0 0.0 67.6 49.0 21.9 29.2 41.2 10.4 31.3 21.8
Missing 0.0 33.3 11.5 0.0 8.4 0.0 1.0 0.0 2.0 5.8 4.2 5.3 8.7 1.9 2.6
Responding pharmacist has a postgraduate qualification in pharmacy 
Yes 52.5 69.6 54.2 5.5 2.2 9.6 0.0 85.2 8.1 9.0 20.4 8.8 37.8 5.9 58.2
Missing 0.0 23.3 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.4 2.0 0.3 2.0 0.3 0.0
Responding pharmacist participates routinely in multidisciplinary team meetings 
Yes 42.4 31.4 25.3 35.4 56.8 27.7 2.5 97.6 15.4 15.4 16.6 19.7 23.5 4.0 25.9
Missing 0.0 22.2 0.0 0.0 0.0 0.0 0.0 0.0 0.7 1.6 2.5 2.1 1.4 0.3 0.0
Pharmacy has a private consultation area 
Yes 68.7 49.3 82.8 71.1 6.6 68.7 1.3 97.6 72.7 91.8 92.6 31.8 77.9 54.0 85.4
Missing 0.0 23.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 1.7 1.6 2.0 0.0 0
Use pharmacy software routinely when checking clinical data 
Yes 50.5 15.3 43.4 7.9 5.7 48.2 0.0 100.0 69.8 51.0 44.6 30.0 41.6 49.2 57.2
Missing 0.0 20.0 0.8 0.0 0.0 0.0 0.3 0.0 0.7 0.0 3.2 4.5 0.0 0.3 0
 
  
    
Use pharmacy software routinely when checking drug-drug-interactions 
Yes 47.5 69.4 98.8 56.5 22.9 56.6 0.0 100.0 88.0 98.0 94.7 29.5 86.7 78.1 98.5
Missing 0.0 20.0 0.1 0.0 0.0 0.0 0.3 0.0 0.0 0.8 3.2 4.8 0.0 0.3 0
Use pharmacy software routinely when checking contraindications 
Yes 54.5 44.4 92.1 56.1 31.7 53.0 0.0 100.0 78.0 84.6 92.3 31.5 75.1 51.9 66.9
Missing 0.0 20.0 0.3 0.0 0.0 0.0 0.3 0.0 0.0 1.2 3.5 5.1 0.0 0.3 0.0
Clinical information about patients available via a shared database 
Yes 40.4 33.3 0.0 0.0 2.2 0.0 0.0 39.1 4.0 10.9 0.0 14.7 13.4 6.7 28.7
Missing 0.0 23.3 0.0 0.0 0.0 0.0 0.0 34.0 0.0 0.0 0.0 0.3 0.9 0.3 0.0
Clinical data about patients easily accessed 
Yes 49.5 26.3 63.4 56.6 38.7 0.0 3.5 41.8 46.9 5.4 37.4 51.5 25.9 32.9 34.2
Missing 0.0 36.7 0.0 0.0 2.2 0.0 0.3 67.9 4.7 12.8 2.2 13.4 14.2 0.3 28.7
Responding pharmacist participates in the following activities 
Health screening 
Yes 50.5 13.9 49.0 75.0 19.8 32.5 1.3 46.4 30.8 57.0 81.6 25.4 35.0 1.9 74.1
Missing 0.0 20.0 0.6 0.0 0.0 0.0 0.0 0.0 2.7 2.3 1.9 3.2 0.0 0.3 0.0
 
  
    
Patient monitoring 
Yes 44.4 9.7 52.0 19.6 15.0 42.2 0.0 18.2 26.4 62.8 28.9 30.1 46.0 4.0 66.9
Missing 0.0 20.0 1.0 0.0 0.0 0.0 0.0 0.0 1.3 1.6 3.2 3.2 0.0 0.3 0.0
Medication review 
Yes 53.5 37.5 65.1 11.2 12.3 13.4 0.0 94.3 66.0 29.4 41.8 68.3 60.1 10.2 64.6
Missing 0.0 20.0 0.4 0.0 0.0 1.2 0.0 0.0 2.0 3.5 3.1 2.1 0.0 0.3 0.0
Health promotion/education 
Yes 58.6 27.8 58.4 79.3 29.5 73.2 1.3 30.1 90.6 41.7 69.4 76.6 77.2 22.7 86.4
Missing 0.0 20.0 0.6 0.0 0.0 1.2 0.0 0.0 0.7 1.9 2.3 2.7 0.0 0.3 0.0 
*In Spain: “Near to health centre”
  
Table 3 Respondents’ scores for the modified BPCS across different European 
countries   (2013) 
 
 
 
 
Country 
Total BPCS 
Score 
(Mean ± SD) 
Direct Patient 
Care 
activities  
(Mean ± SD) 
Referral and 
consultation 
activities  
(Mean ± SD) 
Instrumental 
activities 
(Mean ± SD) 
Bosnia 78.0 ± 10.6 29.4 ± 8.5 24.3 ± 2.5 24.3 ± 2.2 
Denmark 75.6 ± 12.9 26.3 ± 12.8 28.7 ± 5.1 20.8 ± 2.7 
Germany 72.1 ± 22.7 33.0 ± 16.5 20.4 ± 5.5 18.9 ± 3.9 
Italy 57.3 ± 22.4 19.6 ± 14.8 17.0 ± 5.7 20.8 ± 6.0 
Lithuania 60.4 ± 20.8 23.1 ± 14.9 16.7 ± 5.6 20.6 ± 4.9 
Malta 75.6 ± 22.1 29.3 ± 16.0 22.6 ± 6.2 23.7 ± 4.2 
Moldova 47.0 ± 2.1 13.4 ± 1.4 16.3 ± 1.3 17.3 ± 2.1 
Netherlands*  34.8 ± 3  26.6 ± 3.3 
N. Ireland 73.8 ± 20.7 29.2 ± 14.8 20.2 ± 5.2 24.1 ± 4.0 
Norway 66.7 ± 20.1 25.1 ± 15.2 19.3 ± 4.6 22.5 ± 4.2 
Portugal 77.3 ± 21.5 34.8 ± 15.1 20.5 ± 5.5 22.2 ± 4.7 
Serbia 77.5 ± 25.5 32.1 ± 16.8 21.5 ± 6.6 24.0 ± 4.5 
Spain 80.2 ± 14.8 30.8 ± 18.3 28.6 ± 5.7 20.4 ± 4.9 
Sweden 63.2 ± 15.7 24.8 ± 11.1 18.3 ± 4.5 20.2 ± 4.0 
Switzerland 82.7 ± 22.8 41.5 ± 16.5 20.0 ± 5.8 21.2 ± 4.2 
* Total score cannot be computed for the Netherlands, due to a missing item in the Referral and 
consultation activities survey 
 
 
 
 
  
 
Figure 1 Total score for the modified BPCS across different European countries 
(2013) 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 4 Summary of providers and non-providers of pharmaceutical care across the 
European countries surveyed (2013) 
Country Range of total 
BPCS score 
Score range in 
individual 
country for 
providers (top 
25%) 
% of providers 
(top 25%) in 
individual 
country  
Score range in 
individual 
country for 
non-providers 
(bottom 25%) 
% of non-
provider 
(bottom 25%) 
in individual 
country  
Bosnia 46 – 127  106 – 127 1.0 46 – 66 8.2 
Denmark 52 – 108  94 – 108 14.3 52 – 66 24.5 
Germany 22 – 150  118 – 150 4.5 22 – 54 22.5 
Italy 15 – 132  102 – 132 3.7 15 – 44 31.7 
Lithuania 17 – 117  92 – 117   5.7 17 – 42 20.7 
Malta 35 – 146  118 – 146 3.6 35 – 62 28.9 
Moldova 41 – 55  52 – 55 7.4 41 – 44 30.3 
N. Ireland 33 – 133  108 – 133 8.1 33 – 58 19.3 
Norway 23 – 136  108 – 136 2.9 23 – 51 21.6 
Portugal 30 – 143  115 - 143 5.2 30 – 58 19.3 
Serbia 25 – 158  124 – 158 5.8 25 – 59   25.7 
Spain 48 – 123  104 – 123 8.0 48 – 67 18.5 
Sweden 21 – 117   93 – 117 4.3 21 – 45 12.8 
Switzerland 15 – 136  105 – 136 17.4 15 – 46 5.9 
* The Netherlands are not included in the table because the overall score could not be 
calculated
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Table 5 Comparison of BPCS scores restricted to countries participating in both editions 
Country overall BPCS score 2006 2013 p-value* 
Denmark 50.6 75.6   
 
 
 
 
 
 
0.0376 
Germany 70.8 72.1 
Malta 74.1 75.6 
Northern Ireland 74.0 74.1 
Portugal 76.5 77.5 
Sweden 62.9 63.2 
Switzerland 73.2 82.7 
Mean 68.9 74.4 
*Mann-Whitney test (1-tailed p-value) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 33 
 
 
Table 6 Final variables included in the linear regression model relating to total BPCS score 
across all  
European countries surveyed in the current edition 
Variable B (Std. Error) 95.0% 
Confidence 
Interval for B 
p value 
(Constant) 47.903 (0.586) 46.755–49.051 <0.001 
Participation in Medication review 9.901 (0.605) 8.716–11.086 <0.001 
Routinely using pharmacy software 
to check clinical data 9.182 (0.589) 8.028–10.336 <0.001 
Participation in Patient monitoring 7.663 (0.628) 6.432–8.894 <0.001 
Routine Participation in local 
multi-disciplinary team meetings 6.821 (0.621) 5.605–8.038 <0.001 
Participation in Health 
promotion/education 5.333 (0.575) 4.206–6.460 <0.001 
Routinely using pharmacy software 
to check contraindications 3.611 (0.588) 2.458–4.763 <0.001 
Having access to clinical data 
(either through shared database or 
being easily accessed) 
2.823 (0.530) 1.784–3.862 <0.001 
Having a postgraduate qualification 
in pharmacy practice/clinical 
pharmacy 
2.922 (0.639) 1.670–4.174 <0.001 
Having a high prescription volume  0.005 (0.001) 0.002–0.007 <0.001 
Pharmacy with a private 
consultation area 1.787 (0.600) 0.611–2.963 0.003 
 
 
 
